RESUMEN
Significant development has occurred in the treatment of postmenopausal osteoporosis. We review the most recent guidelines from the American Association of Clinical Endocrinologists/American College of Endocrinology, Endocrine Society, and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis/International Osteoporosis Foundation Guidelines.
Asunto(s)
Endocrinología , Osteoporosis Posmenopáusica , Osteoporosis , Densidad Ósea , Endocrinólogos , Femenino , Humanos , Osteoporosis/diagnóstico , Osteoporosis/tratamiento farmacológico , Osteoporosis/etiología , Osteoporosis Posmenopáusica/tratamiento farmacológico , Medición de Riesgo , Estados UnidosRESUMEN
Increasing evidence, albeit small, suggests that testosterone replacement therapy can be cautiously considered in selected hypogonadal men treated with curative intent for low-risk prostate cancer and without evidence of active disease.
RESUMEN
Osteoporosis, a well-defined and growing public health problem, is a disease characterized by increased bone turnover and decreased bone mass with associated skeletal fragility, resulting in an increased risk of fracture. It is often unrecognized until the late stages when fragility fractures have occurred. In adults, early recognition of the disease prior to the occurrence of fractures followed by timely and efficient initiation of appropriate treatment can reduce fracture risk. In this article, we review clinical modalities available to effectively predict fracture risk in patients with osteoporosis. Bone mineral density and presence of clinical risk factors may be combined to provide a more comprehensive osteoporotic fracture risk assessment. Use of FRAX may serve as a general guideline for clinical management and deciding a threshold for cost-effective pharmacological intervention. Elevated bone turnover markers are predictive of high fracture risk and can provide additional clinical information as well.
Asunto(s)
Densidad Ósea , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/fisiopatología , Factores de Edad , Anciano , Anciano de 80 o más Años , Biomarcadores , Índice de Masa Corporal , Remodelación Ósea/fisiología , Comorbilidad , Femenino , Conductas Relacionadas con la Salud , Humanos , Estilo de Vida , Masculino , Persona de Mediana Edad , Factores de RiesgoRESUMEN
Metabolite levels in cerebrospinal fluid from patients with lower back pain and/or sciatica caused by disc herniation or spinal stenosis were compared with levels in pain-free controls using proton magnetic resonance spectroscopy. Significant differences for several metabolites were found in patients with pain compared with controls. Most changes were found in the group with disc herniation, including reductions in glucose, alanine, and lactate, suggesting increased aerobic metabolism in this group. There was a significant reduction in the level of glucose in the group with spinal stenosis irrespective of whether the patients were compared with the whole control group (age-weighted) or with age-matched controls. Additionally, inositol and creatinine were reduced in patients with disc herniation. Inositol was also significantly reduced in the spinal stenosis group when age matched to controls. Insofar as the levels of pain recorded by the patients with lumbar pathology were similar in the two groups, it seems more likely that the reductions in metabolite levels recorded in the group with disc herniations are related to disc pathology rather than the perception of pain. However, the possibility that pain perception contributes to the metabolic changes cannot be excluded.